Form 4: TNF Pharmaceuticals Vice President of Finance Acquires 75,000 Employee Stock Options

Gary Rauch, Vice President of Finance at TNF Pharmaceuticals, acquired 75,000 employee stock options on April 17, 2025, at an exercise price of $0.1832.

Summary

• Gary Rauch, the Vice President of Finance at TNF Pharmaceuticals, acquired 75,000 employee stock options on April 17, 2025.
• The exercise price for these options is $0.1832.
• The options vest on April 18, 2025, and expire on April 16, 2035.
• The reporting person directly owns the options.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition. The acquisition itself can be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Risks

• The stock options are subject to expiration if the employment of the Reporting Person is terminated.

Industry Context

This is a standard SEC Form 4 filing, which is required when an insider of a publicly traded company buys or sells the company's securities. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a company executive can have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, TNF Pharmaceuticals, Form 4, insider trading, Gary Rauch, TNFA, beneficial ownership